Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Fendler A, Shepherd STC, Au L, Wu M, Harvey R, Wilkinson KA, Schmitt AM, Tippu Z, Shum B, Farag S, Rogiers A, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Deng D, Kjaer S, Song OR, Queval CJ, Kavanagh C, Wall EC, Carr EJ, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Popat S, Yousaf N, Jhanji S, Tatham K, Cunningham D, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Wilkinson RJ, Larkin J, Turajlic S. Fendler A, et al. Among authors: turajlic s. Cell Rep Med. 2022 Oct 18;3(10):100781. doi: 10.1016/j.xcrm.2022.100781. Epub 2022 Sep 27. Cell Rep Med. 2022. PMID: 36240755 Free PMC article.
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.
Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Perelli L, et al. Among authors: turajlic s. Nat Cancer. 2023 Jul;4(7):984-1000. doi: 10.1038/s43018-023-00584-1. Epub 2023 Jun 26. Nat Cancer. 2023. PMID: 37365326 Free PMC article.
Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S, Ali Z, Yousaf N, Larkin J. Turajlic S, et al. Expert Opin Investig Drugs. 2013 Jun;22(6):739-49. doi: 10.1517/13543784.2013.797964. Epub 2013 May 6. Expert Opin Investig Drugs. 2013. PMID: 23642225 Review.
Relapse models for clear cell renal carcinoma.
Gulati S, Turajlic S, Larkin J, Bates PA, Swanton C. Gulati S, et al. Among authors: turajlic s. Lancet Oncol. 2015 Aug;16(8):e376-8. doi: 10.1016/S1470-2045(15)00090-X. Lancet Oncol. 2015. PMID: 26248843 No abstract available.
SnapShot: Renal Cell Carcinoma.
Turajlic S, Larkin J, Swanton C. Turajlic S, et al. Cell. 2015 Dec 3;163(6):1556-1556.e1. doi: 10.1016/j.cell.2015.11.026. Cell. 2015. PMID: 26638079 Free article.
127 results